Viktor H. Ahlqvist
banner
ahlqvistviktor.bsky.social
Viktor H. Ahlqvist
@ahlqvistviktor.bsky.social
Epidemiology @Aarhus & @Karolinska
Cheers 😂
September 23, 2025 at 8:38 PM
Going for top read 2025 too
September 22, 2025 at 10:11 PM
September 22, 2025 at 8:44 PM
May 17, 2025 at 9:02 AM
May 17, 2025 at 9:01 AM
Thank you, Magda! 🎉🎉 This will enable even more synergies between us!
March 27, 2025 at 5:15 PM
Thanks mate ! Would not have been possible without your help and support!
March 27, 2025 at 3:54 PM
Hey hey hey. All for the CV mate
March 19, 2025 at 3:56 PM
Loool! Perhaps they are relying on scholar rather than their own publisher link? 😂
March 19, 2025 at 2:50 PM
as would larger cohorts with deep phenotyping, ideally including genetics; I am deeply concerned about genetic confounding, considering the known genetic overlap between both psychiatric and epileptic indications and neurodevelopmental outcomes!
January 11, 2025 at 12:00 PM
And yes, I definitely agree that there is likely residual confounding despite controlling for observed indications and SES. Better data on siblings would be incredibly useful, ...
January 11, 2025 at 12:00 PM
Yes, they were independent of the original safety signals. Lamotrigine has been estimated to not be associated with malformations or neurodevelopmental outcomes in a series of cohorts.
January 11, 2025 at 12:00 PM
It’s all quite challenging. However, we believe we’ve identified some consistent signals for valproate (expected), topiramate (verification of prior findings), and carbamazepine (novel). Whether these hold up under further causal scrutiny remains to be seen...!
January 6, 2025 at 10:19 AM
We tried to adjust for many of these imbalances (inc bipolar indication), but the coverage & quality of the registry data have limitations. This is partly why sibling comparisons are valuable, assuming indications remain somewhat stable across pregnancies (this may not hold for episodic conditions).
January 6, 2025 at 10:19 AM
However, it’s not ideal. As you noted, lamotrigine is also used for bipolar (and on/off-label elsewhere). Also, individuals with more 'severe indications' (e.g., generalized epilepsies) are often treated with e.g. topiramate, introducing differential indication severity even within antiseizure meds.
January 6, 2025 at 10:19 AM
Re Lamotrigine: It is first-line treatment for epilepsy and is generally considered the safest option during pregnancy (not linked to malformations). Using it as a reference, rather than ‘no use,’ has clear advantages – and this approach has been used in the teratology literature.
January 6, 2025 at 10:19 AM
Thanks for the interest, @sebatlab.bsky.social ! Agree that the sibling analysis shows (much) attenuation. However, we’re cautious about overinterpreting the statistical null given our limited power. Still, we believe this highlights the value of such analyses and the promise as samples grow larger.
January 6, 2025 at 10:19 AM